FAM3B, also known as PANcreatic DERived factor (PANDER), promotes gluconeogenesis and lipogenesis in hepatocytes. However, the underlying mechanism(s) still remains largely unclear. This study determined the mechanism of PANDER-induced FOXO1 activation in hepatocytes. In mouse livers and cultured hepatocytes, PAN-DER protein is located in both the cytoplasm and nucleus. Nuclear PANDER distribution was increased in the livers of obese mice. In cultured mouse and human hepatocytes, PANDER was co-localized with FOXO1 in the nucleus. PANDER directly interacted with FOXO1 in mouse and human hepatocytes. PANDER overexpression enhanced PANDER-FOXO1 interaction, and detained FOXO1 in the nucleus upon insulin stimulation in hepatocytes. With the increase in PANDER-FOXO1 interaction, PANDER overexpression upregulated the expression of gluconeogenic genes and promoted gluconeogenesis in both human and mouse hepatocytes. Luciferase reporter assays further revealed that PANDER augmented the transcriptional activity of FOXO1 on gluconeogenic genes. Moreover, PANDER overexpression also interfered the binding of AS1842856, a specific FOXO1 inhibitor, with FOXO1, and impaired its inhibitory effects on gluconeogenic gene expression and gluconeogenesis in hepatocytes. siRNA mediated-silencing of FOXO1 inhibited PANDER-promoted gluconeogenic gene expression and glucose production in hepatocytes. In conclusion, PANDER protein is abundantly present in the nucleus, where it functions as a new co-activator of FOXO1 to induce gluconeogenic gene expression in hepatocytes.
| INTRODUCTION
Family with sequence similarity 3 (FAM3) cytokine-like gene superfamily consists four members designated as FAM3A, FAM3B, FAM3C and FAM3D respectively. 1 In pancreas, FAM3B is highly expressed in the islets, 2, 3 and it is thus also called pancreatic derived factor (PAN-DER). PANDER is co-secreted with insulin in pancreatic β cells upon the stimulation of glucose and other insulin secretagogues. 4 Islet-secreted PANDER contributed to islet β cell dysfunctions under obese or stress conditions. [5] [6] [7] [8] [9] PANDER also binds to the liver membrane and induces insulin resistance. 10 Specific overexpression of PANDER in mouse islets causes hepatic insulin resistance, and enhances gluconeogenesis and lipogenesis, 11, 12 further confirming that the liver is one target tissue of pancreatic-derived PANDER. Moreover, PANDER is also abundantly expressed in the livers of human and rodents, and hepatic PANDER expression is increased under obese condition. 13 Hepatic PANDER overexpression promotes gluconeogenesis and lipogenesis, whereas hepatic PANDER silencing ameliorated fatty liver and hyperglycemia in obese mice. 13, 14 PANDER knockout (PANKO) mice exhibit increased hepatic insulin sensitivity. 15, 16 In humans, increased circulating PANDER levels have been reported to be associated with pancreatic β cell dysfunction, hyperglycemia and insulin resistance in various races. [17] [18] [19] Overall, these clinical and experimental studies had established that PANDER plays important roles in the regulation of glucose and lipid metabolism. [17] [18] [19] [20] In the previous study, 13 we demonstrated that PANDER promotes the lipogenesis in hepatocytes by inhibiting Akt to activate FOXO1. However, whether PANDER activates FOXO1 activity via other mechanism(s) beyond Akt repression remains unknown. So far, whether or not PANDER can be released by other non-islet cell types such as hepatocyte remains unclear. A putative secretory isoform of PANDER had been reported to be detected in the medium of cultured hepatocytes after PANDER overexpression, 14 while the secretory PANDER isoform failed to be detected in mouse livers and cultured hepatocytes in several other studies. 13, 21, 22 Moreover, a non-secretory PANDER isoform has been reported to promote invasion and metastasis of human colon cancer cells. 23 Collectively, these findings had raised an important hypothesis that PANDER may modulate glucose and lipid metabolism via non-secretory mechanism in hepatocytes.
In the current study, we determined that PANDER is abundantly present in the nucleus of both human and mouse hepatocytes.
Under diabetic conditions, nuclear distribution of PANDER is increased in the livers. PANDER directly interacts with FOXO1 to activate it in the nucleus, enhancing gluconeogenic gene expression and promoting gluconeogenesis in hepatocytes.
| MATERIALS AND METHODS

| Animals
Eight-week-old male C57BL/6 mice and 8-to 12-week-old male db/ db and db/m (C57BKS background Jackson Laboratory, USA) were used in this study. 8-10 week old male C57BL/6 mice were fed on 45% high fat diet (HFD) or normal diet (ND) for 12 weeks to induce diabetic and steatotic phenotype as detailed previously. 13, 24 12-to 16-week old male db/db mice and db/m mice on BKS ground were also used in this study.
| Immunohistochemistry
Liver tissues were fixed, dehydrated and embedded in paraffin wax.
Sections (5-μm thick) were incubated with anti-PANDER (1:200, ABclonal, A1082) or IgG as primary antibody overnight at 4°C. Secondary antibodies (Zhongshan Golden Bridge, China) were added for 30 minutes at 37°C. Slides were counterstained with 3,30-diaminobenzidine (DAB) and hematoxylin.
| Mitochondria and cytosol/nuclear fraction isolation
Mitochondria fraction was isolated using Mitochondria Isolation Kit (Applygen Technologies Inc, C1260, China) as detailed previously. 25 In brief, 100 mg mouse liver tissues were homogenized in Mito Solution by glass homogenizer in the ice. All of procedures were in ice or 4°C. Then the lysate was centrifuged twice at 800 g for 5 minutes, then the supernatant was collected and centrifuged at 10 000 g for 10 minutes, the mitochondria precipitated at the bottom of the tube, and cytosolic fraction was in the supernatant. 0.2 ml Mito solution was added to the tube and centrifuged at 12 000 g for 5 minutes to wash the mitochondria at least three times. Finally, the mitochondria were re-suspended in 50 μl Roth lysis buffer for immunoblotting.
| Nuclear cytosol extraction
Nuclear and cytosolic fractions were isolated using the Nuclear Cytosol Extraction Kit (Applygen Technologies Inc, P1200, China). All processes were carried out on ice and all reagents were pre-cooled before the experiment. One hundred milligram mouse liver tissues were homogenized in 1 ml Cytosol Extraction Buffer A (CEB-A) by a glass homogenizer in ice 20-40 times. The lysate was transferred to a pre-cooled 1.5 ml centrifuge tube. After oscillating vigorously for 30 seconds, the lysate was kept on ice for 10-15 minutes, and oscillated for 15 seconds every 5 minutes. Then, 50 μl of Cytosol Extraction Buffer B (CEB-B) was added, and the mixture was oscillated for 10 seconds. After placing on ice for 1 minute, the lysis was centrifuged at 1000 g for 5 minutes at 4°C. The precipitation was a nuclear crude extraction and the supernatant was a crude cytoplasmic protein component. The supernatant was transferred to another pre-cooled centrifuge tube, and centrifuged at 12 000 g at 4°C for 10 minutes. The supernatant is cytosol protein component. 100 μl CEB-A and 5 μl CEB-B were added to the raw nuclear extraction and vortexed for 10 seconds, then the mixture was incubated on ice for 1 minute and centrifuged at 1000 g for 5 minutes at 4°C, the procedure was repeated again. One hundred microlitre pre-cooled 
| Primary mouse hepatocytes culture
Primary mouse hepatocytes were cultured as detailed previously. 24 Briefly, the mouse liver was perfused with 50 mL Kreb solution, followed by 30 mL Kreb solution with collagenase type Ι to digest the liver. The cells were filtered with a metal mesh using 1640 medium; the cells were then washed and centrifuged at 50 g at 4°C for three times. The cells were cultured with 1640 containing 10% FBS for 6-8 hours at 37°C with 5% CO 2 before treating.
| Cell culture
The human hepatocarcinoma cell line (HepG2) was purchased from 
| Glucose production assays
The experimental procedure for glucose production was detailed in previous study. 24 In brief, HepG2 cells were infected with Ad-GFP or Ad-PANDER for 30 hours and then washed by PBS for three times.
Cells were incubated in glucose production buffer (glucose and phenol red-free DMEM medium with 20 mmol L -1 sodium lactate and 2 mmol L -1 sodium pyruvate) with or without FOXO1 inhibitor AS1842856
(1 μmol L -1 ). After culture for 13 hours, 10 nmol L -1 insulin was added to the cells and treated for 3 hours. Cell culture supernatants were collected and centrifuged at 1000 g for 5 minutes, the supernatants were used to analyse glucose content using Glucose Assay Kit (SigmaAldrich, . The glucose content was normalized by the cellular protein content in each sample (µg/mg protein), and then the data were normalized to the control value. were added to the coverslips and incubated for 1 hour. The nucleus was stained with DAPI for 10 minutes, and 50% glycerol in PBS was used to mount the coverslips on glass slides. Mounted coverslips were imaged and cells were visualized by fluorescence microscopy using Confocal Laser Scanning Microscope.
| Confocal imaging assay
| RNA extraction and real time-PCR assays
Total RNA was extracted from HepG2 cells by TRIzol reagent (Invitrogen, USA), and cDNA was synthesized by cDNA Synthesis Kit (Thermo, USA). Quantitative real-time PCR was performed using SYBR Green PCR Master Mix (TOYOBO, Japan). The relative levels of the target gene mRNAs were calculated by 2 −ΔΔCt methodology using β-actin as house-keeping gene. All the primers for PCR assays were listed in Table S1 .
| Immunoblotting assays
Total protein was extracted from mouse livers or HepG2 cells using Roth and data were normalised to β-actin protein expression. respectively. 50 μl of 5X loading buffer containing 0.2 mmol L -1 DTT was added. The samples were mixed and boiled at 100°C for 10 minutes, and then centrifuged at 13 000 g for 2 minutes. Twenty microlitres of the supernatant was separated by 10% sodium dodecyl sulphate (SDS) gel, and immunoblotting assays were then performed.
| Immunoprecipitation
| Luciferase reporter assay
The fragment of mouse G6pase gene promoter flanking −1360 bp to +2 bp which contains four FOXO1 binding sites 26 University, China). The protocol for promoter activity assay was detailed previously. 24 The pG6pase promoter-firefly luciferase and pRL-TK-Renilla luciferase were cotransfected with FOXO1 plasmid or FOXO1 and PANDER plasmid or GFP plasmid into HepG2 cells using Nucleic Acid Technology Co., Ltd) for 12 hours. At 12 hours posttransfection, the medium was replaced with fresh medium, and cells were infected with 50 MOI of Ad-GFP, Ad-FOXO1 or Ad-PANDER for 24 hours before glucose production was determined. All the siRNA sequences were listed in Table S2 .
| Statistical analysis
Data were displayed as the mean ± SEM, and statistical differences between two groups were analysed by t tests. P < 0.05 was considered statistically significant.
| RESULTS
| PANDER is abundantly expressed in the nucleus of mouse and human hepatocytes
To probe the mechanism of liver-derived pancreatic derived factor (PANDER) in regulation of hepatic glucose and lipid metabolism in hepatocytes, its subcellular distribution was determined by immunohistochemical (IHC) staining and confocal imaging analyses in mouse livers and cultured hepatocytes. In mouse livers, IHC staining revealed that PANDER protein is present in both the cytoplasm and nucleus ( Figure 1A ). Confocal imaging further confirmed the presence of PANDER protein in both the cytoplasm and nucleus of mouse livers ( Figure S1 ). To further validate the subcellular distribution of PANDER protein, mitochondrial, cytosolic and nuclear fractions were isolated respectively. As a result, PANDER protein is present in both cytosolic and nuclear fractions, but not in mitochondrial fraction of mouse livers ( Figure 1B) . PANDER protein detected in the current study is a full length isoform with the molecular weight of 26kD. Generally, the secretory PANDER isoform (22kD) in mouse livers and cultured hepatocytes cannot be effectively detected. Confocal imaging analyses further confirmed that PANDER protein is abundantly present in the nucleus of primary mouse hepatocytes ( Figure 1C ) and human HepG2 cells ( Figure 1D ).
Quantitative assays further showed that about 50%-60% of PAN-DER protein is distributed in the nucleus of primary mouse hepatocytes ( Figure 1E ), whereas about 70% of it is present in the nucleus of human HepG2 cells ( Figure 1F ). Overall, these findings clearly indicated that PANDER protein is abundantly present in the nucleus of both human and mouse hepatocytes.
| Nuclear PANDER distribution is increased in the livers of obese diabetic mice
Abundant distribution of PANDER in the nucleus suggested that it may impact hepatic glucose metabolism via the intracellular mechanism beyond secretion. To determine the role of nuclear PANDER in the pathogenesis of diabetes, its expression was analysed in the livers of obese diabetic mice. As a result, total PANDER expression was increased in db/db mouse livers (Figure 2A ), which is consistent with the previous findings. 13 Determination of subcellular PANDER content revealed that nuclear PANDER distribution was significantly increased, whereas its cytosolic distribution remained unchanged in db/db mouse livers when compared with db/m mouse livers (Figure 2A) . In high fat diet (HFD)-fed obese mouse livers, the total PANDER expression was also increased when compared with normal diet (ND)-fed mouse livers. Furthermore, both nuclear and cytosolic PANDER distributions were increased in HFD mouse livers when compared with normal mouse livers ( Figure 2B ). Overall, these findings revealed that nuclear PANDER distribution was increased in the mouse livers under obese condition.
| PANDER interacts with FOXO1 in mouse and human hepatocytes
Because both PANDER and FOXO1 distributions were increased in the livers under diabetic conditions, and PANDER overexpression or silencing increased or decreased FOXO1 protein level in mouse livers, 13 ,27 whether a direct interaction existed between them was further determined. Firstly, confocal imaging revealed that PANDER is co-localized with FOXO1 in the nucleus of primary mouse hepatocytes ( Figure 3A) . Similarly, PANDER is also co-localized with FOXO1 
| PANDER co-activates FOXO1 to upregulate gluconeogenic genes and promote gluconeogenesis in hepatocytes
FOXO1 plays a decisive role in regulating gluconeogenesis by controlling the expression of two key gluconeogenic genes, PEPCK and G6Pase, in hepatocytes. 28 Because PANDER overexpression increased PANDER-FOXO1 interaction, whether it increased Consistently, PANDER overexpression stimulated gluconeogenesis in HepG2 cells ( Figure 7D ). PANDER overexpression similarly stimulated glucose production in primary mouse hepatocytes ( Figure 7E ).
Then, whether PANDER directly stimulated the transcriptional activity of FOXO1 was further evaluated using luciferase reporter driven by mouse G6pase gene promoter. As a result, FOXO1 significantly activated the promoter activity of mouse G6pase gene, and PANDER overexpression augmented the activation ( Figure 7F ).
In contrast, a mutant PANDER with the mutations of Cys91 and Cys229, which form one disulphide bond, to serines, failed to augment FOXO1 transcriptional activity ( Figure 7F ). The mutant PANDER cannot be processed and released from pancreatic β cells due to the change of structure. 
| DISCUSSION
In a Chinese population, circulating PANDER is increased in patients with metabolic syndrome. In particular, circulating PANDER can predict the risk of type 2 diabetes in Chinese population. 17 Another clinical report confirmed that serum PANDER level is increased in patients with metabolic syndrome, and an increase in circulating PANDER level can predict metabolic syndrome in Chinese population. 29 An increase in serum PANDER levels have been reported to be associated with pancreatic β cell dysfunction and hyperglycemia in other races. 18, 19 Overall, these important clinical studies revealed that circulating PANDER is a unique diagnostic biomarker for diabetes and metabolic syndrome, and it is necessary to further study the mechanism(s) of PANDER in the regulation of glucose and lipid metabolism.
In the current study, we demonstrated that PANDER protein is abundantly present in the nucleus of both human and mouse hepatocytes. Under diabetic conditions, nuclear PANDER distribution was the main mechanism for its activity repression. 30 In addition, cyclindependent kinase 2 (CDK2) and MAPK/ERK signalling pathways also phosphorylate FOXO1 to inhibit it. 31 In oxidative stress, CREB binding protein (CBP) acetylates the lysine residues in the DNA binding area of FOXO1, interfering its binding with the promoters of target genes. 32 In our previous study, we had demonstrated that PANDER overexpression elevated FOXO1 protein level with Akt repression, whereas PANDER inhibition reduced FOXO1 protein level with Akt activation in mouse livers and cultured hepatocytes. 13 The current study further revealed that PANDER activates [36] [37] [38] which can be phosphorylated and inactivated by Akt, to induce gluconeogenic gene expression by repressing Akt in hepatocytes. 13 Collectively, the current and previous findings revealed that PANDER regulates hepatic FOXO1 activity by inducing Akt repression 13 and functioning as a direct co-activator. We and others had demonstrated that FOXO1 overexpression induces the expression of both gluconeogenic and lipogenic genes in mouse livers. 13, 39 Given that overactivation of FOXO1 plays critical roles in triggering hepatic gluconeogenesis and lipogenesis, 27, 30, 39, 40 targeting PANDER-FOXO1 interaction will be beneficial for diabetes and fatty liver.
So far, the region in PANDER protein which directly interacts with FOXO1 still remains unknown. Mapping the binding region of PANDER protein with FOXO1 will be helpful for further 
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